IFIT3 is a novel biomarker for human ischemic cardiomyopathy that can inhibit the nuclear factor-kappa B (NF-κB) pathway in injured arteries, resulting in the inhibition of endothelial cell proliferation, migration, and re-endothelialization [39]. Here, NFKB1 is linked to ischemic cardiomyopathy.